IRIS UniCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.632
EU - Europa 3.497
AS - Asia 3.166
SA - Sud America 594
AF - Africa 95
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.005
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.506
SG - Singapore 1.406
DE - Germania 1.111
CN - Cina 808
SE - Svezia 519
BR - Brasile 476
NL - Olanda 376
IT - Italia 352
VN - Vietnam 271
FR - Francia 262
UA - Ucraina 201
IN - India 149
PL - Polonia 142
IE - Irlanda 129
GB - Regno Unito 116
ID - Indonesia 92
RU - Federazione Russa 74
FI - Finlandia 71
BD - Bangladesh 59
JP - Giappone 59
CA - Canada 55
HK - Hong Kong 55
TR - Turchia 48
MX - Messico 41
AR - Argentina 38
IQ - Iraq 35
ZA - Sudafrica 31
ES - Italia 29
PK - Pakistan 26
SA - Arabia Saudita 23
KR - Corea 20
NO - Norvegia 19
BE - Belgio 18
AT - Austria 16
CO - Colombia 16
EC - Ecuador 15
AU - Australia 13
CL - Cile 13
CI - Costa d'Avorio 12
JO - Giordania 12
UZ - Uzbekistan 12
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
MA - Marocco 10
PH - Filippine 10
CZ - Repubblica Ceca 9
IR - Iran 9
LT - Lituania 9
EG - Egitto 8
PY - Paraguay 8
BO - Bolivia 7
GR - Grecia 7
JM - Giamaica 7
KE - Kenya 7
MY - Malesia 7
NP - Nepal 7
PE - Perù 7
PS - Palestinian Territory 7
TH - Thailandia 7
DZ - Algeria 6
IL - Israele 6
RO - Romania 6
AZ - Azerbaigian 5
CH - Svizzera 5
KZ - Kazakistan 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
HU - Ungheria 4
TN - Tunisia 4
BB - Barbados 3
BG - Bulgaria 3
CR - Costa Rica 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
AO - Angola 2
BW - Botswana 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
DK - Danimarca 1
FJ - Figi 1
GF - Guiana Francese 1
IS - Islanda 1
KH - Cambogia 1
Totale 11.987
Salva come PNG Salva come JPEG
Città #
Singapore 806
Chandler 559
San Jose 468
Ashburn 381
Amsterdam 350
Frankfurt am Main 159
Jacksonville 142
Beijing 137
Chicago 137
Los Angeles 136
Warsaw 127
Dublin 123
New York 121
San Mateo 113
Ann Arbor 109
Dearborn 97
Houston 97
Ho Chi Minh City 95
Woodbridge 95
Nanjing 94
Munich 90
Jakarta 83
Wilmington 83
Lauterbourg 82
Milan 70
Hefei 69
Hanoi 66
St Louis 62
Buffalo 58
Fairfield 57
Boston 55
São Paulo 53
Hong Kong 52
Rome 48
Moscow 47
Tokyo 47
Hyderabad 46
Dallas 45
Bremen 44
The Dalles 44
Cattolica 41
Nürnberg 40
Seattle 39
Nanchang 37
Redwood City 37
Santa Clara 37
Lawrence 34
Princeton 34
Marseille 27
Shanghai 27
Hangzhou 26
Salt Lake City 26
London 25
Montreal 25
Orem 25
Council Bluffs 23
Leawood 20
Shenyang 20
Cambridge 19
Mountain View 19
Brussels 18
Da Nang 18
Guangzhou 18
Kunming 18
Tianjin 18
Brooklyn 17
Izmir 17
Redmond 17
Seoul 17
Boardman 16
Chatsworth 16
Paris 16
Pune 16
Augusta 15
Kent 15
Poplar 15
Auburn Hills 14
Denver 14
Johannesburg 14
Mexico City 14
Atlanta 13
Baghdad 13
Dhaka 13
Elk Grove Village 13
Falls Church 13
Jiaxing 13
Nuremberg 13
Tampa 13
Zhengzhou 13
Abidjan 12
Amman 12
Belo Horizonte 12
Chennai 12
Hebei 12
Lappeenranta 12
Changsha 11
Norwalk 11
Philadelphia 11
Phoenix 11
Rio de Janeiro 11
Totale 6.695
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 587
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 435
Fanconi anemia gene variants in therapy-related myeloid neoplasms 327
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 249
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 241
Why methylation is not a marker predictive of response to hypomethylating agents 202
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 202
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 196
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 191
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 190
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 189
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 186
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 185
Epigenetic changes in therapy-related MDS/AML 183
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 183
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 181
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 176
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 176
Clonal evolution in therapy-related neoplasms 176
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 175
Similarities and differences between therapy-related and elderly acute myeloid leukemia 171
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 170
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 167
Primary plasma cell leukemia followed by testicular plasmacytoma 165
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 158
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 156
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 152
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 152
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 150
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 149
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 149
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 145
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 144
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 139
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 139
Outcome of therapy-related myeloid neoplasms treated with azacitidine 138
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 135
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 134
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 134
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 133
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 133
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 131
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 128
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 128
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 127
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 123
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 122
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 121
Therapy-related myeloid neoplasms: Clinical perspectives 119
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 118
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 117
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 112
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 109
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 107
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 106
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 105
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 105
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 105
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 103
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 102
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 101
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 101
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 101
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 99
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 98
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 97
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 97
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 96
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 96
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 95
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 94
Fungaemia in haematological malignancies: SEIFEM-2015 survey 92
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 90
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 87
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 87
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 85
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 84
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 82
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 81
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 81
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 78
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 70
Mastocytosis: One Word for Different Diseases 69
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 67
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 59
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide 3
Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study 3
Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia 2
Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms 2
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 2
Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update 1
Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review 1
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report 1
Totale 12.133
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/2022693 64 40 8 29 51 35 13 122 37 72 96 126
2022/20231.452 188 207 123 267 77 181 50 110 157 20 52 20
2023/2024736 37 186 27 27 29 131 60 15 11 26 90 97
2024/20251.856 49 58 129 54 155 24 90 73 228 171 563 262
2025/20264.607 605 92 223 412 680 780 739 196 340 340 125 75
Totale 12.133